Condition (MeSH)
Myoclonic Epilepsies, Progressive
ClinicalTrials.gov lists 21 trials for Myoclonic Epilepsies, Progressive or a narrower condition beneath it. PTC Therapeutics has the most among industry and government lead sponsors, with 2.
Search trials, drugs, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Trials per phase
11 of the 21 trials are tagged with Myoclonic Epilepsies, Progressive itself; the rest are tagged with a narrower condition beneath it.
When did Myoclonic Epilepsies, Progressive trials start? (12)
Shown in this order: most recent first, 1990 onwards. 2026 is partial: trials registered with a 2026 start date so far, not a full year.
Trials over time, by phase
- Phase 1
- Phase 1/2
- Phase 2
- Phase 2/3
- Phase 3
- Observational
Top of scale: 4
Trials registered with a start date in each year, 1990 onward, stacked by phase (complete years only; the current partial year is in the table's notes). The table below lists the same counts, most recent years first.
| Year | Trials started |
|---|---|
| 2025 | 1 |
| 2024 | 4 |
| 2023 | 3 |
| 2022 | 2 |
| 2020 | 1 |
| 2019 | 1 |
| 2015 | 1 |
| 2011 | 1 |
| 2009 | 1 |
| 2007 | 1 |
Showing 10 of 12 earlier years.
No forecast is made for this condition: it averages 2.0 trial starts a year over the five years to September, under the 5 a year the method needs.
Recruitment duration, a model prediction: 2 trials still running at the 2026-10-09 snapshot, fewer than the 5 needed for a median. Source: ClinicalTrials.gov / AACT (CTTI), public domain.
What phase are Myoclonic Epilepsies, Progressive trials in? (7)
Shown in this order: phase order.
Show the trials by phase as a table
| Phase | Trials |
|---|---|
| Phase 1 | 1 |
| Phase 1/2 | 5 |
| Phase 2 | 2 |
| Phase 2/3 | 1 |
| Phase 3 | 4 |
| Observational | 7 |
| Expanded access | 1 |
How many Myoclonic Epilepsies, Progressive trials are recruiting? (6)
Shown in this order: the order a trial moves through, from not yet recruiting to unknown.
| Status | Trials |
|---|---|
| Recruiting | 4 |
| Active, not recruiting | 3 |
| Available | 1 |
| Completed | 9 |
| Terminated | 1 |
Showing 5 of 6 statuses.
Status as registered on ClinicalTrials.gov. Each trial is counted once.
Which lead sponsors run the most Myoclonic Epilepsies, Progressive trials? (8)
Shown in this order: most trials first. Lead sponsors the registry classes as industry, NIH, US federal, other government or network. A hospital or university the registry files as government can appear here. Sponsors it classes as academic or other are shown on the full page, because that class cannot separate an institution from a named investigator.
| Sponsor | Trials |
|---|---|
| PTC Therapeutics | 2 |
| Autifony Therapeutics Limited | 1 |
| Ionis Pharmaceuticals, Inc. | 1 |
| National Human Genome Research Institute (NHGRI) | 1 |
| National Institute of Neurological Disorders and Stroke (NINDS) | 1 |
Showing 5 of 8 sponsors.
Which drugs are being tested for Myoclonic Epilepsies, Progressive? (5)
Shown in this order: most trials first. One row per drug, matched to a single molecule under all its names, ranked by number of trials.
| Drug | Trials |
|---|---|
| EPI-743 | 2 |
| Ropinirole | 1 |
| OMT-28 | 1 |
| VAL-1221 | 1 |
| Immunoglobulin | 1 |
Interventions as named in the registry (7)
Shown in this order: most trials first.
| Drug | Trials |
|---|---|
| nL-ATN1-002 | 2 |
| BRV 25 mg | 1 |
| BRV 2.5 mg | 1 |
| nL-ATN1-001 | 1 |
| BRV 50 mg | 1 |
Showing 5 of 7 interventions.
These are the names sponsors entered on ClinicalTrials.gov that we have not matched to a single molecule. Some are drugs under a brand or code name; others are procedures, doses or arm labels.
Which serious adverse events do Myoclonic Epilepsies, Progressive trials report? (10)
Shown in this order: most subjects affected first. Subjects affected summed across trials, a cross-trial signal, not a rate.
| Adverse event | Subjects affected | Trials |
|---|---|---|
| Pneumonia | 20 | 2 |
| Seizure | 14 | 2 |
| Acute respiratory failure | 11 | 1 |
| COVID-19 | 10 | 2 |
| Vomiting | 10 | 2 |
Showing 5 of 10 adverse events.
Which publications cover Myoclonic Epilepsies, Progressive? (7)
Shown in this order: major-topic papers first, then newest, then most linked to trials.
| Publication | Journal | Year | Major topic |
|---|---|---|---|
| ASAH1 pathogenic variants associated with acid ceramidase deficiency: Farber disease and spinal muscular atrophy with progressive myoclonic epilepsy. | Human mutation | 2020 | Yes |
| Novel mutations consolidate KCTD7 as a progressive myoclonus epilepsy gene. | Journal of medical genetics | 2012 | Yes |
| Transarterial embolisation for refractory bilateral chronic subdural hematomas in a case with dentatorubral-pallidoluysian atrophy. | Acta neurochirurgica | 2011 | Yes |
| Prevalence of dentatorubral-pallidoluysian atrophy in a large series of white patients with cerebellar ataxia. | Archives of neurology | 2003 | Yes |
| Abnormal in vivo skeletal muscle energy metabolism in Huntington's disease and dentatorubropallidoluysian atrophy. | Annals of neurology | 2000 | Yes |
Showing 5 of 7 publications.
Rare-disease identity (2)
Shown in this order: exact, broader, narrower, other.
| Orphanet disease | ORPHA code | Relation | Source |
|---|---|---|---|
| Progressive myoclonic epilepsy | 98261 | Exact | Orphadata Science knowledge files, Product 1 |
| Progressive myoclonic epilepsy | 98261 | Exact | Orphanet Rare Disease Ontology (ORDO) |
Sub-conditions in MeSH (3)
MeSH descendants one level down with at least one trial, most trials first.
Not on this page
Not measured: delivery record.
Checked, with nothing recorded for this condition: prevalence.